Imaging cancer using single photon techniques

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 49, Issue 2, 2005, Pages 121-131

  Buscombe, J R ^a   Bombardieri, E ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Computed toography; Neoplasms; Radionuclide imaging; Single photon, emission computed

Indexed keywords

CLINICAL PRACTICE; CLINICAL TRIAL; HUMAN; IMAGE ENHANCEMENT; METHODOLOGY; NEOPLASM; PRACTICE GUIDELINE; REVIEW; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CLINICAL TRIALS; HUMANS; IMAGE ENHANCEMENT; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33646815216     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Bombardieri E, Crippa F. The increasing impact of PET in the diagnostic work-up of cancer patients. In: Freeman LM, editor. Nuclear medicine annual 2002. Philadelphia: Lippincott Williams and Wilkins; 2002.p.75-121.
2. Schillaci O, Simonetti G. Fusion imaging in nuclear medicine: applications of dual-modality systems in oncology. Cancer Biother Radiopharm 2004;19:1-10. (Pubitemid 38352280)
3. Savelli G, Maffioli L, Maccauro M, De Deckere E, Bombardieri E. Bone scintigraphy and the added value of SPET (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med 2001;45:27-37. (Pubitemid 32586339)
4. Horger M, Eschmann SM, Pfannenberg C, Vonthein R, Besenfelder H, Claussen CD et al. Evaluation of combined transmission and emission tomography for classification of skeletal lesions. AJR Am J Roentgenol 2004;183:655-61.
5. Even-Sapir E, Lerman H, Lievshitz G, Khafif A, Fliss DM, Schwartz A et al. Lymphoscintigraphy for sentinel node mapping using a hybrid SPET/CT system. J Nucl Med 2003;44:1413-20. (Pubitemid 39663353)
6. Sluyser M, Hoefnagel CA. Breast carcinomas detected by thallium-201 scintigraphy. Cancer Lett 1988;40:161-8.
7. Terui S, Terauchi T, Abe H, Fukuma H, Beppu Y, Chuman K et al. On clinical usefulness of Tl-201 scintigraphy for the management of malignant soft tissue tumors. On clinical usefulness of Tl-201 scintigraphy for the management of malignant soft tissue tumors. Ann Nucl Med 1994;8:55-64. (Pubitemid 24118956)
8. Roach PJ, Cooper RA, Arthur CK, Ravich RB. Comparison of thallium-201 and gallium-67 scintigraphy in the evaluation of non-Hodgkin's lymphoma. Aust N Z J Med 1998;28:33-8.
9. Vertosick FT Jr, Selker RG, Grossman SJ, Joyce JM. Correlation of thallium-201 single photon emission computed tomography and survival after treatment failure in patients with glioblastoma multiforme. Neurosurgery 1994;34:396-401.
10. Demir H, Berk F, Erdincler O, Isgoren S, Aktolun C. Tl-201 imaging in the diagnostic work-up of squamous cell carcinoma metastasis of unknown primary origin. Clin Nucl Med 2002;27:385-6. (Pubitemid 34437692)
11. Kline JL, Noto RB, Glantz M. Single-photon emission CT in the evaluation of recurrent brain tumor in patients treated with gamma knife radiosurgery or conventional radiation therapy. Am J Neuroradiol 1996;17:1681-6. (Pubitemid 26354775)
12. 201Tl-SPET. Am J Neuroradiol 1998;19:801-6.
13. Liu HG, Mountz JM. F-18 FDG brain positron emission tomography and Tl-201 early and delayed SPET in distinguishing atypical cerebral tumor from cerebral infarction. Clin Nucl Med 2003;28:241-2.
14. Ruiz A, Ganz WI, Post MJ, Camp A, Landy H, Mallin W et al. Use of thallium-201 brain SPET to differentiate cerebral lymphoma from toxoplasma encephalitis in AIDS patients. Am J Neuroradiol 1995;15:1885-94. (Pubitemid 24352834)
15. 201Tl SPET in the detection of recurrent brain tumours after radiation therapy. Nucl Med Commun 2002;23:1183-90. (Pubitemid 36026980)
16. Caner B, Kitapci M, Aras T, Erbengi G, Ugur O, Bekdik C. Increased accumulation of hexakis (2-methoxyisobutylisonitrile)technetium(I) in osteosarcoma and its metastatic lymph nodes. J Nucl Med 1991;32:1977-8.
17. Aktolun C, Bayhan H, Kir M. Clinical experience with Tc-99m MIBI imaging in patients with malignant tumors. Preliminary results and comparison with Tl-201. Clin Nucl Med 1992;17: 171-6.
18. Szybinski Z, Huszno B, Golkowski F, Atneisha A. Technetium 99m-methoxyisobutylisonitrile in early diagnosis of thyroid cancer. Endokrynol Pol 1993;44:427-33.
19. Basoglu T, Sahin M, Coskun C, Koparan A, Bernay I, Erkan L. Technetium-99m-tetrofosmin uptake in malignant lung tumours. Eur J Nucl Med 1995;22:687-9.
20. Kao CH, Wang SJ, Liu TJ. The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses. Eur J Nucl Med 1994;21:432-6.
21. Khalkhali I, Mena I, Jouanne E, Diggles L, Venegas R, Block J et al. Prone scintimammography in patients with suspicion of carcinoma of the breast. J Am Coll Surg 1994;178:491-7. (Pubitemid 24141506)
22. Palmedo H, Biersack HJ, Lastoria S, Maublant J, Prats E, Stegner HE et al. Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentre trial. Eur J Nucl Med 1998;25:375-85.
23. 99mTc-sestamibi breast imaging: multicenter trial results. J Nucl Med 2000;41:1973-9. (Pubitemid 32038685)
24. Buscombe JR, Cwikla JB, Holloway B, Hilson AJ. Prediction of the usefulness of combined mammography and scintimammography in suspected primary breast cancer using ROC curves. J Nucl Med 2001;42:3-8. (Pubitemid 32104769)
25. Buscombe JR, Hall ML, Smith A, Sheppick A. Results of a multicentre trial in the use of Myoview in breast imaging and identifying primary breast cancer. Radiology 2000;217:500P.
26. 99mTc-MIBI identify multifocal and multicentric primary breast cancer? Nucl Med Commun 2001;22:1287-93.
27. Vargas HI, Agbunag RV, Kalinowski A, Tolmos J, Klein SR, Diggles L et al. The clinical utility of Tc-99m sestamibi scintimammography in detecting multicentric breast cancer. Am Surg 2001;67:1204-8.
28. Madeddu G, Spanu A. Use of tomographic nuclear medicine procedures, SPET and pinhole SPET, with cationic lipophilic radiotracers for the evaluation of axillary lumph nodes status in breast cancer patients. Eur J Nucl Med Mol Imaging 2004;31 Suppl 1:23-34. (Pubitemid 38833031)
29. Schillaci O, Buscombe JR. Breast scintigraphy today: indications and limitations. Eur J Nucl Med Mol Imaging 2004; Suppl 1:35-45. (Pubitemid 38833032)
30. Obwegeser R, Berghammer P, Rodrigues M, Granegger S, Hohlagschwandtner M, Kucera H et al. A head-to-head comparison between technetium-99m-tetrofosmin and technetium-99m-MIBI scintigraphy to evaluate suspicious breast lesions. Eur J Nucl Med 1999;26:1553-9.
31. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 1990;82:1826-38.
32. Del Vecchio SD, Ciarmiello A, Potena MI, Carriero MV, Mainolfi C, Botti G et al. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 1997;24:150-9.
33. Cwikla JB, Buscombe JR, Barlow RV, Kelleher SM, Parbhoo SP, Crow J et al. The effect of chemotherapy on the uptake of technetium-99m sestamibi in breast cancer. Eur J Nucl Med 1997;24:1175-8.
34. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston RB. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. Cancer 1999;85:2410-23.
35. 99mTc-MIBI Imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and p-glycoprotein expression. J Nucl Med 2003;44:1394-401.
36. Hsu WH, Yen RF, Kao CH, Shiun SC, Hsu NY, Lin CC et al. Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer (stage IIIb or IV) with a higher T stage (>T2). Technetium-99m methoxyisobutylisonitrile chest single photon emission computed tomography and P-glycoprotein express ion. Oncology 2002;63:173-9.
37. Lavender JP, Lowe J, Barker JR, Burn JI, Chaudhri MA. Gallium 67 citrate scanning in neoplastic and inflammatory lesions. Br J Radiol 1971;44:361-6.
38. Keidar Z, Israel O, Krausz Y. SPET/CT in tumor imaging: technical aspects and clinical applications. Semin Nucl Med 2003;33:205-18.
39. Gallamini A, Biggi A, Fruttero A, Pugno F, Cavallero G, Pregno P et al. Revisiting the prognostic role of gallium scintigraphy in low-grade non-Hodgkin's lymphoma. Eur J Nucl Med 1997;24:1499-506.
40. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148-55.
41. Bakker WH, Krenning EP, Breeman WA, Koper JW, Kooij PP, Reubi JC et al. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals. J Nucl Med 1990;31: 1501-9.
42. Bakker WH, Krenning EP, Breeman WA, Kooij PP, Reubi JC, Koper JW et al. In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man. J Nucl Med 1991;32:1184-9. Erratum in: J Nucl Med 1991;32:1999.
43. Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Splinter TA, Kho GS et al. Radioiodinated somatostatin analog scintigraphy in small-cell lung cancer. J Nucl Med 1991;32:1845-8.
44. Limouris GS, Rassidakis A, Kondi-Paphiti A, Triantafyllou N, Manetou A, Giannakopoulos V et al. Somatostatin receptor scintigraphy of non-neuroendocrine malignancies with 111In-pentetreotide. Anticancer Res 1997;3B:1593-7.
45. Lipp RW, Schnedl WJ, Aglas F, Ranner G, Beham-Schmid C, Leb G et al. Visualization of non-Hodgkin's lymphoma by high dosed somatostatin receptor specific scintigraphy and extended single photon emission tomography. Acta Med Austriaca 1999;26:105-8. (Pubitemid 29441154)
46. Rubini G, D'Eredita G. Tc-99m sestamibi and In-111 DTPA octreotide uptake in breast carcinoma with neurendocrine differentiation. Clin Nucl Med 2000;25:482-3. (Pubitemid 30327329)
47. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998;25:79-83. (Pubitemid 28107907)
48. Pfannenberg AC, Eschmann SM, Horger M, Lamberts R, Vonthein R, Claussen CD et al. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging 2003;30:835-43. (Pubitemid 36734202)
49. 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 2003;59:565-73. (Pubitemid 37357615)
50. 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3]octreotide. Bioconjug Chem 1999;10:431-8.
51. Grewal RK, Dadparvar S, Yu JQ, Babaria CJ, Cavanaugh T, Sherman M et al. Efficacy of Tc-99m depreotide scintigraphy in the evaluation of solitary pulmonary nodules. Cancer J 2002;8:400-4.
52. de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3] octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24:368-71.
53. Behr TM, Jenner N, Behe M, Angerstein C, Gratz S, Raue F et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 1999;40:1029-44. (Pubitemid 29269226)
54. 99mTc bombesin. A preliminary report. Tumori 2002;88:S25-8.
55. Raderer M, Kurtaran A, Yang Q, Meghdadi S, Vorbeck F, Hejna M et al. Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer. J Nucl Med 1998;39:1570-5. (Pubitemid 28276761)
56. 111In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998. J Clin Oncol 2000;18:1331-6.
57. Signore A, Annovazzi A, Chianelli M, Corsetti F, Van de Wiele C, Watherhouse RN. Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med 2001;28:1555-65.
58. Petronis JD, Regan F, Lin K. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med 1998;23:672-7. (Pubitemid 28487326)
59. Feneley MR, Chengazi VU, Kirby RS, Nimmon CC, Granowska M, Mather SJ et al. Prostatic radioimmunoscintigraphy: preliminary results using technetium-labelled monoclonal antibody, CYT-351. Br J Urol 1996;77:373-81.
60. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999;36:31-5. (Pubitemid 29265277)
61. Moffat FL Jr, Pinsky CM, Hammershaimb L, Petrelli NJ, Patt YZ, Whaley FS et al. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group. J Clin Oncol 1996;14:2295-305.
62. Goldenberg DM, Wegener W. Studies of breast cancer imaging with radiolabeled antibodies to carcinoembryonic antigen. Immunomedics Breast Cancer Study Group. Acta Med Austriaca 1997;24:55-9.
63. Yagcloglu H, Ozalp E, Ibis E, Aras G. Partial stunning in thyroid remnant after administration of scanning dose followed by 100 mCi I-131 therapy. Clin Nucl Med 1996;21:340.
64. Mandel SJ, Shankar LK, Benard F, Yamamoto A, Alavi A. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med 2001;26:6-9.
65. 131I-SPET/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging 2004;31:1435-42.
66. Smit JW, Shroder-van der Elst JP, Karperien M, Que I, van der Pluijm G, Goslings B et al. Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line. Thyroid 2000;10:939-43.
67. Cho JY, Shen DH, Yang W, Williams B, Buckwalter TL, La Perle KM et al. In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas. Gene Ther 2002;9:1139-45.
68. Lynn MD, Shapiro B, Sisson JC, Swanson DP, Mangner TJ, Wieland DM et al. Portrayal of pheochromocytoma and normal human adrenal medulla by m-123I-iodobenzylguanidine: concise communication. J Nucl Med 1984;25:436-40.
69. Ali-el-Dein B, el-Sobky E, el-Baz M, Shaaban AA. Abdominal and pelvic extra-adrenal paraganglioma: a review of literature and a report on 7 cases. In Vivo 2002;16:249-54.
70. 123I-MIBG scintigraphy. Nuklearmedizin 2004;43:164-70.
71. Cook GJ, Houston S, Barrington SF, Fogelman I. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. J Nucl Med 1998;39:99-103.
72. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003;9:571-9. (Pubitemid 36182586)
73. Li S, Peck-Radosavljevic M, Kienast O, Preitfellner J, Hamilton G, Kurtaran A et al. Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. Ann Oncol 2003;14:1274-7.
74. Vriens PW, Blankenberg FG, Stoot JH, Ohtsuki K, Berry GJ, Tait JF et al. The use of technetium Tc 99m annexin V for in vivo imaging of apoptosis during cardiac allograft rejection. J Thorac Cardiovasc Surg 1998;116:844-53.
75. Van de Wiele C, Philippe J, Van Haelst JP, Van Damme J, Thierens H, Leroux-Roels GE et al. Relationship of decreased chemotaxis of technetium-99m-HMPAO-labeled lymphocytes to apoptosis. J Nucl Med 1997;38:1417-21. (Pubitemid 27386203)